Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis
暂无分享,去创建一个
T. Masszi | F. Nicolini | N. Gallagher | B. Powell | M. Zheng | A. Turkina | S. Jootar | Zhixiang Shen | P. Dorlhiac-Llacer | T. Szczudlo | Z. Shen